Paper Details

  1. Home
  2. Paper Details

eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort.

Author: AragãoFilipa, BerenguerJuan, CastañoManuel, DeigElisabeth, Diaz-CuervoHelena, DomingoPere, EspinosaNuria, EstradaVicente, GalindoPepa, GarcíaJosefina, GeijoPaloma, MartínezElisa, MerinoMaríaDolores, MonteroMarta, MuñozJosefa, PeraireJoaquim, RiberaEsteve, RocaBernardino, RomeroAlberto, SepúlvedaMaría Antonia, TeiraRamón, de la FuenteBelén

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Switching from emtricitabine/tenofovir disoproxil fumarate (F/TDF) to emtricitabine/tenofovir alafenamide (F/TAF)-based triple-therapy regimens resulted in numerical improvements in eGFR-EPI for people living with HIV (PLWH) with baseline eGFR-EPI <90 ml/min/1.73m<sup>2</sup>. Switching to F/TAF demonstrated beneficial renal effects in a clinical practice setting.
Paper Details　
Original Abstract of the Article :
<b>Background:</b> Evidence from clinical practice on the effects of switching from emtricitabine/tenofovir disoproxil fumarate (F/TDF) to emtricitabine/tenofovir alafenamide (F/TAF)-based triple-therapy (TT) regimens on renal parameters is limited.<b>Objective:</b> This retrospective analysis eval...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/25787489.2021.1955197

データ提供：米国国立医学図書館（NLM）

Switching Antiretroviral Therapy: A Potential Oasis for Renal Function in HIV Patients

Navigating the complex [treatment of HIV] is a journey with many twists and turns, and researchers constantly seek ways to improve patient outcomes. This study, like a careful navigator, examined the effects of switching from [emtricitabine/tenofovir disoproxil fumarate (F/TDF)] to [emtricitabine/tenofovir alafenamide (F/TAF)]-based regimens in patients with HIV. Their retrospective analysis revealed that, much like a nourishing oasis in the desert, switching to F/TAF was associated with a numerical improvement in [estimated glomerular filtration rate (eGFR-EPI)], particularly in patients with baseline eGFR-EPI below 90 ml/min/1.73m2. This finding suggests that switching to F/TAF may provide renal protection for patients with HIV.

A New Path to Renal Health: Switching to F/TAF

The study found that switching from F/TDF to F/TAF resulted in a significant improvement in [eGFR-EPI] over time in patients with baseline [eGFR-EPI] below 90 ml/min/1.73m2. This finding, like a well-maintained path leading to a lush oasis, suggests that switching to F/TAF may offer a promising approach to preserving renal function in patients with HIV.

Protecting the Oasis: Considering Renal Health in HIV Treatment

This research emphasizes the importance of monitoring [renal function] in patients with HIV and considering the potential benefits of switching to F/TAF-based regimens. Just as a camel carefully conserves water in the desert, we must be mindful of preserving renal health in individuals with HIV. This study provides valuable insights for making informed treatment decisions that promote both viral suppression and renal health.

Dr.Camel's Conclusion

This study highlights the importance of carefully considering the potential benefits of switching to F/TAF-based regimens for patients with HIV. Just as a camel adapts to its desert environment, we must be adaptable and innovative in our approach to HIV treatment, seeking out the most effective and well-tolerated therapies to improve patient outcomes.

Date :
  1. Date Completed 2021-10-25
  2. Date Revised 2021-10-25
Further Info :

Pubmed ID

34410219

DOI: Digital Object Identifier

10.1080/25787489.2021.1955197

Related Literature

Article Analysis
・Effects of emtricitabine and tenofovir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.